Drug combination shows long-term survival in advanced thymic cancer
Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma.
Read original article on The Medical News →Related news
-
Can a scent really sharpen your memory? It's complicated
United Kingdom
-
Air pollution exposure tied to atopic dermatitis in children
United Kingdom
-
RNA switch lets drugs control gene therapy protein production
United Kingdom
-
Is there an opening for Nvidia's competitors, now that Jensen Huang is out?
United States
-
Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria
United Kingdom
-
GLP-1s often contain untested additive combinations, study finds
United Kingdom
-
New body map traces origins of complex movements in the brains of mice
United Kingdom
-
AI Adds Capacity. People Don’t Scale the Same Way: Lessons on Sustainable Operations
United States